These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 2558314)
1. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC). Dubinsky RM; Yarchoan R; Dalakas M; Broder S Muscle Nerve; 1989 Oct; 12(10):856-60. PubMed ID: 2558314 [TBL] [Abstract][Full Text] [Related]
2. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Skowron G; Bozzette SA; Lim L; Pettinelli CB; Schaumburg HH; Arezzo J; Fischl MA; Powderly WG; Gocke DJ; Richman DD; Pottage JC; Antoniskis D; McKinley GF; Hyslop NE; Ray G; Simon G; Reed N; LoFaro ML; Uttamchandani RB; Gelb LD; Sperber SJ; Murphy RL; Leedom JM; Grieco MH; Zachary J; Hirsch MS; Spector SA; Bigley J; Soo W; Merigan TC Ann Intern Med; 1993 Mar; 118(5):321-30. PubMed ID: 8094279 [TBL] [Abstract][Full Text] [Related]
3. 2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Berger AR; Arezzo JC; Schaumburg HH; Skowron G; Merigan T; Bozzette S; Richman D; Soo W Neurology; 1993 Feb; 43(2):358-62. PubMed ID: 8382349 [TBL] [Abstract][Full Text] [Related]
4. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Yarchoan R; Perno CF; Thomas RV; Klecker RW; Allain JP; Wills RJ; McAtee N; Fischl MA; Dubinsky R; McNeely MC Lancet; 1988 Jan; 1(8577):76-81. PubMed ID: 2891981 [TBL] [Abstract][Full Text] [Related]
5. Alternating and intermittent regimens of zidovudine (3'-azido-3'-deoxythymidine) and dideoxycytidine (2',3'-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Skowron G; Merigan TC Am J Med; 1990 May; 88(5B):20S-23S. PubMed ID: 2159705 [TBL] [Abstract][Full Text] [Related]
6. Peripheral neuropathy induced by 2',3'-dideoxycytidine. A rabbit model of 2',3'-dideoxycytidine neurotoxicity. Anderson TD; Davidovich A; Arceo R; Brosnan C; Arezzo J; Schaumburg H Lab Invest; 1992 Jan; 66(1):63-74. PubMed ID: 1309930 [TBL] [Abstract][Full Text] [Related]
7. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Merigan TC; Skowron G; Bozzette SA; Richman D; Uttamchandani R; Fischl M; Schooley R; Hirsch M; Soo W; Pettinelli C Ann Intern Med; 1989 Feb; 110(3):189-94. PubMed ID: 2536257 [TBL] [Abstract][Full Text] [Related]
8. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC). Dalakas MC; Semino-Mora C; Leon-Monzon M Lab Invest; 2001 Nov; 81(11):1537-44. PubMed ID: 11706061 [TBL] [Abstract][Full Text] [Related]
9. Mechanically-evoked C-fiber activity in painful alcohol and AIDS therapy neuropathy in the rat. Chen X; Levine JD Mol Pain; 2007 Feb; 3():5. PubMed ID: 17319957 [TBL] [Abstract][Full Text] [Related]
10. [New, in Austria registered specialty drugs. Hivid (2',3'-dideoxycytidine; ddC)]. Töglhofer W Wien Klin Wochenschr; 1992; 104(12):363-7. PubMed ID: 1353278 [No Abstract] [Full Text] [Related]
11. AIDS Clinical Trials Group: phase I/II study of combination 2',3'-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex. Meng TC; Fischl MA; Richman DD Am J Med; 1990 May; 88(5B):27S-30S. PubMed ID: 2159707 [TBL] [Abstract][Full Text] [Related]
12. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. Pizzo PA; Butler K; Balis F; Brouwers E; Hawkins M; Eddy J; Einloth M; Falloon J; Husson R; Jarosinski P J Pediatr; 1990 Nov; 117(5):799-808. PubMed ID: 2172501 [TBL] [Abstract][Full Text] [Related]
13. Ultrastructure of peripheral neuropathy induced in rabbits by 2',3'-dideoxycytidine. Feldman D; Brosnan C; Anderson TD Lab Invest; 1992 Jan; 66(1):75-85. PubMed ID: 1309931 [TBL] [Abstract][Full Text] [Related]
14. Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Merigan TC; Skowron G Am J Med; 1990 May; 88(5B):11S-15S. PubMed ID: 2159703 [TBL] [Abstract][Full Text] [Related]
15. Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity. Anderson TD; Davidovich A; Feldman D; Sprinkle TJ; Arezzo J; Brosnan C; Calderon RO; Fossom LH; DeVries JT; DeVries GH Lab Invest; 1994 May; 70(5):724-39. PubMed ID: 7515130 [TBL] [Abstract][Full Text] [Related]
16. The RNA-binding protein HuD promotes spinal GAP43 overexpression in antiretroviral-induced neuropathy. Sanna MD; Quattrone A; Mello T; Ghelardini C; Galeotti N Exp Neurol; 2014 Nov; 261():343-53. PubMed ID: 24861443 [TBL] [Abstract][Full Text] [Related]
17. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2',3'-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate. Keilbaugh SA; Hobbs GA; Simpson MV Mol Pharmacol; 1993 Oct; 44(4):702-6. PubMed ID: 8232219 [TBL] [Abstract][Full Text] [Related]
18. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. Kieburtz KD; Seidlin M; Lambert JS; Dolin R; Reichman R; Valentine F J Acquir Immune Defic Syndr (1988); 1992; 5(1):60-4. PubMed ID: 1346633 [TBL] [Abstract][Full Text] [Related]
19. A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex. Gustavson LE; Fukuda EK; Rubio FA; Dunton AW J Acquir Immune Defic Syndr (1988); 1990; 3(1):28-31. PubMed ID: 2152803 [TBL] [Abstract][Full Text] [Related]